<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300404</url>
  </required_header>
  <id_info>
    <org_study_id>TOXO-KI-TT</org_study_id>
    <secondary_id>SMRI grant # 01T-404</secondary_id>
    <nct_id>NCT00300404</nct_id>
  </id_info>
  <brief_title>Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression</brief_title>
  <official_title>Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zentrum für Integrative Psychiatrie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zentrum für Integrative Psychiatrie</source>
  <brief_summary>
    <textblock>
      We investigate whether the add-on specific antitoxoplasmatic medication has positive effects
      in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG)
      infection. As TG modulates neurotransmitter metabolism affecting serotonin and dopamine we
      hypothesize that this chronic persistent infection might play a role for depressive and
      psychotic symptomatology. Therefore, on the basis of an ex juvantibus approach, specific anti
      TG medication might further improve psychiatric symptomatology in affected patients. This is
      investigated in a double-blind, placebo-controlled, randomized treatment trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychopathology ratings</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>TG infection parameters</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Major Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daraprim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pyrimethamine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folinic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia or Major Depression

          -  Both genders

          -  Adult

          -  Patients are able to give informed consent

        Exclusion Criteria:

          -  Additional diagnosis of substance abuse/dependency

          -  Continuous treatment with medication not compatible with study medication

          -  Medical status not compatible with study medication

          -  Any condition that increases study risk considerably

          -  Pregnancy, nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dunja Hinze-Selch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zentrum für Integrative Psychiatrie</affiliation>
  </overall_official>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2006</study_first_posted>
  <last_update_submitted>May 19, 2006</last_update_submitted>
  <last_update_submitted_qc>May 19, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2006</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <keyword>Psychosis</keyword>
  <keyword>Depression</keyword>
  <keyword>Affective Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

